Drugs / Dichlorphenamide
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | KEVEYIS | — | 2015-08-07 – 2019-11-22 | fda.gov ↗ |
| Approved | US (FDA) | KEVEYIS | — | 1958-07-22 | fda.gov ↗ |
Trials 1
195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00004802 | Jun 1992 → ? | hyperkalemic periodic paralysis, hypokalemic periodic paralysis, paramyotonia congenita of Von Eulenburg | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00494507 Comparator | Jun 2007 → Apr 2013 | hyperkalemic periodic paralysis, hypokalemic periodic paralysis | University of Rochester | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Xeris Pharmaceuticals | Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® xerispharma.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dichlorphenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00494507 ↗ |
| Known as | Daranide | ChEMBL registry synonym — accepted as the source's own label CHEMBL17 ↗ |
| Known as | DCP | “Patients are randomly assigned to oral dichlorphenamide (DCP) or placebo for 9 weeks and then cross to the alternate treatment.” NCT00004802 ↗ |
| Known as | Diclofenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL17 ↗ |
| Known as | Diclofenamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL17 ↗ |
| Known as | Keveyis | ChEMBL registry synonym — accepted as the source's own label CHEMBL17 ↗ |
| Known as | Oratrol | ChEMBL registry synonym — accepted as the source's own label CHEMBL17 ↗ |
| Action | Inhibit | “Carbonic anhydrase XII inhibitor” CHEMBL17 ↗3“Carbonic anhydrase IV inhibitor” CHEMBL17 ↗ “Carbonic anhydrase II inhibitor” CHEMBL17 ↗ “Carbonic anhydrase I inhibitor” CHEMBL17 ↗ |
| Modality | Small molecule | — CHEMBL17 ↗ |
| Route | Oral | “Patients are randomly assigned to oral dichlorphenamide (DCP) or placebo for 9 weeks and then cross to the alternate treatment.” NCT00004802 ↗ |
| Target | CA1 | “Carbonic anhydrase I inhibitor” CHEMBL17 ↗ |
| Target | CA12 | “Carbonic anhydrase XII inhibitor” CHEMBL17 ↗ |
| Target | CA2 | “Carbonic anhydrase II inhibitor” CHEMBL17 ↗ |
| Target | CA4 | “Carbonic anhydrase IV inhibitor” CHEMBL17 ↗ |